Ambrx Biopharma Cayman, Inc.
Ambrx Biopharma Cayman, Inc. (AMAM): 4 pipeline candidates · ~54 mo cash runway. Updated within the last hour.
BioSniper Score
4-factor signal · derived from public data
54.1 months
D/E 0.12 · 0% dilution
Lead: Phase 3
4 candidates
N/A
N/A
A transparent, data-derived signal for Ambrx Biopharma Cayman, Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
—
Cash
$228.9M
Quarterly Burn
$13.2M
Runway
54.1 mo
Revenue
$1.1M
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (4 candidates)
Frequently asked questions
How many drug candidates are in Ambrx Biopharma Cayman, Inc.'s pipeline?
Ambrx Biopharma Cayman, Inc. (AMAM) has 4 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is Ambrx Biopharma Cayman, Inc.'s lead drug candidate?
Ambrx Biopharma Cayman, Inc.'s most advanced tracked candidate is arx102 (Preclinical) for Immuno-oncology applications.
What is Ambrx Biopharma Cayman, Inc.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, Ambrx Biopharma Cayman, Inc. has approximately 54.1 months of cash runway.
Who is the CEO of Ambrx Biopharma Cayman, Inc.?
San Diego is the chief executive officer of Ambrx Biopharma Cayman, Inc. (AMAM).
Get the full picture on Ambrx Biopharma Cayman, Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.